Some investors closely monitor the portfolios of billionaires to get ideas. Another approach, however, is to examine the stocks held by highly successful companies. Recursion looks like a big dud so ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Recursion Pharmaceuticals (RXRX) closed the last trading session at $8.59, gaining 20% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recursion Pharmaceuticals (NasdaqGS:RXRX) reports its ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...